J. Andersen

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 905 citations

Tamoxifen Treatment, Clinical Effectiveness, Medicine +8

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

Martine Piccart, K. Bertelsen, Gavin Stuart et al. · International Journal of Gynecological Cancer · 2003 · 122 citations

The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study.

Elisabeth Paietta, J. Andersen, Robert E. Gallagher et al. · PubMed · 1994 · 121 citations

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer

Ann Knoop, P.A. Andreasen, J.A. Andersen et al. · British Journal of Cancer · 1998 · 104 citations · Full text

Urology, Plasminogen Activator Inhibitor-1, Breast Oncology +11

Neural networks for automatic scoring of arthritis disease activity on ultrasound images

J. Andersen, Jannik Skyttegaard Pedersen, Martin Sundahl Laursen et al. · RMD Open · 2019 · 83 citations · Full text